Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer.

Amy J WeismanStephanie A HarmonTimothy G PerkJens EickhoffPeter L ChoykeKaren A KurdzielWilliam L DahutJohn L HummAndrea B ApoloSteven M LarsonMichael J MorrisScott B PerlmanGlenn LiuRobert Jeraj

Published in: Prostate cancer and prostatic diseases (2018)

NaF PET bone flare was present on 61% of mCRPC patients in the first 6 weeks of treatment with CYP17A1-inhibitors. Characterization provided in this study suggests favorable PFS in patients showing bone flare. This characterization of NaF flare is important for guiding treatment assessment schedules to better distinguish between patients showing bone flare and those truly progressing, and should be performed for all emerging mCRPC treatments and imaging agents.

Keyphrases

pet ct
end stage renal disease
ejection fraction
newly diagnosed
squamous cell carcinoma
bone mineral density
prognostic factors
small cell lung cancer
computed tomography
soft tissue
body composition
pet imaging